GlassScriptPhysician profile
Anna Housman
NPI 1609161694
$6,022.66
in general payments reported to CMS, 2019-2025
28 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $1,141 · 2023: $1,221 · 2024: $1,619 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,578 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,578.27 |
| Education | $122.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $791.67 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $737.81 | 2021-2025 | |
| Madrigal Pharmaceuticals | $616.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $576.21 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $464.60 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $275.71 | 2021-2025 | Stelara, Tremfya |
| Celgene Corporation | $272.92 | 2021-2024 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $233.46 | 2022-2023 | Imfinzi |
| Novo Nordisk INC | $232.47 | 2022-2023 | Wegovy |
| Genzyme Corporation | $222.21 | 2023-2025 | |
| Gilead Sciences, INC. | $218.87 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $208.63 | 2023-2025 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $198.00 | 2022 | |
| Aimmune Therapeutics, INC. | $189.00 | 2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $137.65 | 2023-2024 | Rebyota |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $111.99 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $111.56 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $70.81 | 2025 | |
| Intra-Sana Laboratories | $50.00 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Regeneron Healthcare Solutions, INC. | $43.30 | 2023 | Dupixent |
| Exact Sciences Corporation | $41.36 | 2025 | Cologuard Collection Kit |
| Celltrion USA INC. | $39.22 | 2024-2025 | Vegzelma, Zymfentra |
| Evoke Pharma, INC. | $37.84 | 2024-2025 | |
| Braintree Laboratories, INC. | $33.78 | 2024-2025 | Sutab, Suflave |
| Pfizer INC. | $30.54 | 2024 | |
| Qol Medical, LLC | $30.25 | 2025 | Sucraid |
| Orphalan INC | $23.57 | 2024 | Cuvrior |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.76 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Housman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.